What is Eyevensys?
Eyevensys is a privately held biotechnology firm established in 2008 and headquartered in Paris, France. The company is dedicated to pioneering a novel approach to treating a wide spectrum of ophthalmic diseases. Its core innovation lies in enabling the sustained intraocular production of therapeutic proteins, offering a potentially transformative treatment modality for patients. The company's focus on this specialized area positions it within the competitive landscape of biopharmaceutical development for ocular conditions.
How much funding has Eyevensys raised?
Eyevensys has raised a total of $43.7M across 3 funding rounds:
Series A
$1.7M
Series B
$30M
Series B
$12M
Series A (2016): $1.7M with participation from Pontifax
Series B (2020): $30M, investors not publicly disclosed
Series B (2021): $12M supported by Korea Investment Holdings
Key Investors in Eyevensys
Pontifax
Pontifax Venture Capital is a venture capital firm specializing in groundbreaking innovations in life sciences, focusing on transformative healthcare technologies across all development stages. They actively scout disruptive ideas and build exceptional companies, providing hands-on guidance and networking to maximize success.
Korea Investment Holdings
Korea Investment Holdings is a major financial firm in Korea, formed through the merger of a leading investment trust distributor and a prominent securities brokerage. It specializes in asset management, securities brokerage, investment banking, and derivatives trading, playing a significant role in the Korean capital market.
What's next for Eyevensys?
The recent major strategic investment in Eyevensys, following its Series B funding, suggests the company is poised for significant scaling and advancement of its clinical pipeline. This enterprise-level capital infusion is likely earmarked for accelerating research and development, expanding clinical trial operations, and potentially preparing for future regulatory submissions. The strategic nature of the financing indicates strong confidence from investors in Eyevensys's technology and its potential to address unmet needs in the ophthalmology market, paving the way for future growth and market penetration.
See full Eyevensys company page
